Cedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
Curr Oncol. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199.
A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.
一位 32 岁的女性患有化疗耐药性苗勒管腺肉瘤，在接受仑伐替尼联合帕博利珠单抗治疗后显示出临床获益。在本病例报告中，我们描述了她的疾病过程和对这种治疗的反应。
